

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE HealthTech Programme

Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

Final Stakeholder List

Manufacturer

Abbott Medical
Medtronic Limited
Boston Scientific LTD
BIOTRONIK UK LTD
B. Braun Medical Limited
GAP Medical Solutions
Biosensors International UK Limited
Sahajanand Medical Technologies (SMT)
Terumo

External Assessment Group

Centre for Healthcare Evaluation, Device Assessment and Research (CEDAR)

Core stakeholders

Association of British Healthcare Industries (ABHI)
Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
British Cardiovascular Intervention Society
British Cardiovascular Society (BCS)
British Heart Foundation
British Pain Society
Department of Health and Social Care
Device Access
Devices for Dignity
Health Innovation Network
Health Technology Wales
Healthcare Improvement Scotland
HealthTech Alliance
Medicines and Healthcare Products Regulatory Agency
MedTech Strategies
NHS Digital
NHS Supply Chain
NHSE

NHSE Specialised Commissioning
NHSE Transformation
Society of Cardiothoracic Surgeons
The British In Vitro Diagnostics Association (BIVDA)
Welsh Government

Others who register

Professional Experts
Abbott Medical UK Ltd
Beckton Dickinson (BD)
Cook Medical
Health Analytical Solutions
Inomed Healthcare
PENTAG
University Hospital Wales

Definitions:

Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, companies, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).